-
HutchMed’s Tazverik Receives Conditional Approval from China’s NMPA for Lymphoma Treatment
•
China-based HutchMed (NASDAQ: HCM, HKG: 0013) has announced receiving conditional marketing approval from the National Medical Products Administration (NMPA) for its drug Tazverik (tazemetostat), an EZH2 methyltransferase inhibitor. The approval allows Tazverik to treat relapsed or refractory (R/R) follicular lymphoma (FL) with EZH2 mutations in patients who have previously received…
-
Ipsen Appoints Olivia Brown as Global Head of Neurotoxins, Effective April 1st
•
France-based pharmaceutical company Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced the appointment of Olivia Brown as Executive Vice-President (EVP), Global Head of Neurotoxins, effective April 1st, 2025. In her new role, Olivia will lead Ipsen’s global neurotoxins franchise, overseeing strategy and execution across both therapeutic and aesthetic indications. Olivia Brown’s…
-
Ipsen Posts 8.7% Revenue Growth in 2024, Driven by Rare Diseases and Oncology
•
French biopharma firm Ipsen (EPA: IPN, OTCMKTS: IPSEY) reported an 8.7% year-on-year (YOY) increase in global revenues to €3.4 billion ($3.57 billion) for 2024, according to its annual financial report. Core operating profit rose 10.8% YOY to €1.109 billion ($1.165 billion), driven by strong performances across all business sectors. Sector…
-
Ipsen Secures Global Licensing Agreement for Biomunex Pharmaceuticals’ BMX-502 T Cell Engager
•
France-based Ipsen (OTCMKTS: IPSEY) has announced a significant global licensing agreement with compatriot firm Biomunex Pharmaceuticals concerning the latter’s T cell engager (TCE), BMX-502. Ipsen is poised to secure exclusive development, manufacturing, and commercialization rights for BMX-502 across global territories. Responsibilities and Milestones Under the AgreementUnder the terms of the…
-
Ipsen S.A. Receives NMPA Green Light for Six-Month Diphereline Dosage in Central Precocious Puberty
•
Ipsen S.A. (EPA: IPN; OTCMKTS: IPSEY) has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its six-month dosage form of Diphereline (triptorelin), a treatment for central precocious puberty (CPP), a condition that leads to early sexual development in children. This makes Diphereline the…
-
Ipsen Strikes Global Licensing Deal with Foreseen Biotechnology for First-in-Class ADC FS001
•
Ipsen (EPA: IPN; OTCMKTS: IPSEY), a French biopharmaceutical company, has announced a global licensing agreement with Chinese startup Foreseen Biotechnology for the latter’s lead pipeline candidate, FS001. This agreement grants Ipsen exclusive rights to develop, manufacture, and commercialize the antibody-drug conjugate (ADC) on a global scale. As per the terms…
-
Ipsen’s Somatuline Receives First Prescription in China for GEP-NETs Treatment
•
French biopharmaceutical company Ipsen (EPA: IPN; OTCMKTS: IPSEY) has announced that the first prescription of its Somatuline (lanreotide) sustained-release injection has been issued in China for the treatment of gastrointestinal pancreatic neuroendocrine tumors (GEP-NETs). Somatuline, the only somatostatin analogue (SSA) for deep subcutaneous self-injection, received approval in China in December…
-
Ipsen Secures FDA Approval for Onivyde Regimen as First-Line Treatment for Metastatic Pancreatic Adenocarcinoma
•
Ipsen (EPA: IPN, OTCMKTS: IPSEY), the France-based biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for the NALIRIFOX regimen, which combines Onivyde (irinotecan liposome injection) with oxaliplatin, fluorouracil, and leucovorin. This new approval allows for the use of the regimen as…
-
ClouDr Partners with Ipsen to Expand Diphereline’s Reach in China
•
Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), known as “ClouDr,” has partnered with French pharmaceutical company Ipsen S.A. (Euronext: IPN; ADR: IPSEY) regarding Ipsen’s Diphereline (triptorelin), a natural gonadotropin-releasing hormone (GnRH) agonist analog. Financial details of the partnership were not disclosed. ClouDr is a one-stop chronic disease management…
-
Bloomage Biotech Terminates Medytox Pact Over Botox Supply Issues
•
China-based Bloomage Biotech (SHA: 688363) announced that its wholly owned subsidiary, Gentix Limited, has issued a lawyer’s letter to South Korea-headquartered Medytox Inc. on July 29, 2022, seeking to terminate the agreement between the two companies related to Botox and other medical aesthetics products. The move comes after no products…
-
Tris Pharma and Pediatrix’s Methylphenidate Tablet, Ipsen’s Triptorelin Injection Awarded Priority Review by CDE
•
The Center for Drug Evaluation (CDE) website shows that US-based Tris Pharma and Pediatrix Therapeutics’ methylphenidate hydrochloride sustained release chewable tablets, along with Ipsen Pharma’s injectable pamoic acid triptorelin injection, have been granted priority review status. The drugs are recognized for aligning with new pediatric drug varieties, dosage forms, and…
